The Next Biotech say's......

MMJ’s Medical Cannabis Pill Performs Better than A$1.2BN Capped Competitor

Medical cannabis is grabbing all the headlines.
Earlier this week, barnstorming legislation changes introduced by the Australian Federal Government left big pharmaceutical companies scrambling.
Proposed amendments to laws would allow for cultivation, processing and distribution of cannabis for medical purposes through a national licensing and permit scheme.
Plucky epitomes of entrepreneurship otherwise known as medical cannabis growers/suppliers are now clamoring for a piece of the industry…
MMJ Phytotech (ASX:MMJ) has put themselves at the front of the queue to start commercialising medical cannabis as and when government officials give the green light.

Currently, MMJ is a medical grade cannabis company that captures value from the entire ‘Farm to Pharma’ value chain – from cultivation and processing through to pharmaceutical development.
The good news for MMJ is that while medical cannabis friendly legislation is being worked on, it already has a growing operation in Canada on the verge of opening its doors later this year.
MMJ’s Duncan facility in Canada recently played host to pre-license inspectors, in the final stage towards license approval.
The only outstanding part of the equation is a high quality product that’s approved by regulators…
…but that’s exactly what MMJ has just achieved.
Phase 1 clinical trials have just completed indicating MMJ’s “formulations are the same or even higher performance level compared to GW Pharmaceutical’s product”.

GW Pharmaceuticals (LON:GWP) just happens to be a £622MN (A$1.2BN) giant that’s currently the only company to have its medical cannabis product approved by the US Food & Drug Administration (FDA)…
This is a positive sign as any that the product MMJ is looking to produce is of the highest global standards.
Remember, however, that MMJ is still a junior player in an emerging market, and success for the company is speculative. Investment caution is advised.
With its product standing shoulder-to-shoulder with the industry’s best, the A$38MN-capped MMJ now has all the pieces to deliver on its ‘farm-to-pharma’ strategy and become a dominant medical cannabis industry player.

http://www.nextbiotech.com.au/mmjs-...source=SD&utm_medium=edm&utm_content=20160212